These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3897455)

  • 1. Hypothesis: bromocriptine lacks intrinsic dopamine receptor stimulating properties.
    Jackson DM; Jenkins OF
    J Neural Transm; 1985; 62(3-4):219-30. PubMed ID: 3897455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice.
    Jenkins OF; Jackson DM
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Oct; 331(1):7-11. PubMed ID: 3877878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further studies on the interaction between bromocriptine and SKF38393 in reserpine and alpha methyl-para-tyrosine-treated mice.
    Jackson DM; Ross SB; Hashizume M
    Psychopharmacology (Berl); 1988; 94(3):321-7. PubMed ID: 2895938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mode of action of bromocriptine following pretreatment with reserpine and alpha-methyl-p-tyrosine in rats.
    Ushijima I; Mizuki Y; Yamada M
    Psychopharmacology (Berl); 1988; 95(1):29-33. PubMed ID: 2898789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine induces climbing behaviour: possible D-1 or D-2 dopamine receptor involvement.
    Zarrindast MR; Shahed-Dirin K
    Psychopharmacology (Berl); 1990; 100(2):275-80. PubMed ID: 2305016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.
    Johnson AM; Loew DM; Vigouret JM
    Br J Pharmacol; 1976 Jan; 56(1):59-68. PubMed ID: 943193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromocriptine enhances the behavioural effects of apomorphine and dopamine after systemic or intracerebral injection in rats.
    Jenkins OF; Jackson DM
    Neuropharmacology; 1986 Nov; 25(11):1243-9. PubMed ID: 3796797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice.
    Svensson A; Carlsson A; Carlsson ML
    J Neural Transm Gen Sect; 1992; 90(3):199-217. PubMed ID: 1363051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolite involvement in bromocriptine-induced circling behaviour in rodents.
    Reavill C; Jenner P; Marsden CD
    J Pharm Pharmacol; 1980 Apr; 32(4):278-84. PubMed ID: 6103058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of dopamine receptor agonist treatment on haloperidol-induced supersensitivity in mice.
    Fayle P; Jackson DM; Jenkins OF; Lafferty PA
    Pharmacol Biochem Behav; 1985 Nov; 23(5):715-20. PubMed ID: 4080755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between endogenous dopamine and dopamine agonists at release modulatory receptors: multiple effects of neuronal uptake inhibitors on transmitter release.
    Hoffmann IS; Talmaciu RK; Cubeddu LX
    J Pharmacol Exp Ther; 1986 Aug; 238(2):437-46. PubMed ID: 2942676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of dopamine agonists on locomotion in intact and reserpine-treated mice.
    Zarrindast MR; Eliassi A
    Gen Pharmacol; 1991; 22(6):1027-31. PubMed ID: 1687393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of age on behavioral responses to dopamine agonists in the rat.
    Ushijima I; Mizuki Y; Soeda K; Kishimoto O; Hara T; Yamada M
    Eur J Pharmacol; 1987 Jun; 138(1):101-6. PubMed ID: 2887433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J
    Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral evidence for supersensitivity after chronic bromocriptine administration.
    Smith RC; Strong JR; Hicks PB; Samorajski T
    Psychopharmacology (Berl); 1979 Feb; 60(3):241-6. PubMed ID: 108701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of dopaminergic neurotransmission in the hypermotility response produced by the administration of N-methyl-D-aspartic acid into the nucleus accumbens.
    Boldry RC; Uretsky NJ
    Neuropharmacology; 1988 Jun; 27(6):569-77. PubMed ID: 2901677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
    Hu XT; Wachtel SR; Galloway MP; White FJ
    J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple receptors for brain dopamine in behavior regulation: concept of dopamine-E and dopamine-I receptors.
    Cools AR; van Rossum JM
    Life Sci; 1980 Oct; 27(14):1237-53. PubMed ID: 6255271
    [No Abstract]   [Full Text] [Related]  

  • 20. Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF38393.
    Jackson DM; Hashizume M
    Psychopharmacology (Berl); 1986; 90(1):147-9. PubMed ID: 3094056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.